Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study (Q44885072)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

1 reference

based on heuristic

inferred from title

4

object named as

Seock-Ah Im

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

7

object named as

Masakazu Toi

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

author name string

Louis W C Chow

1

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Stewart Y Tung

2

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Ting-Ying Ng

3

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Min-Hyuk Lee

5

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Adrian Y S Yip

6

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Stefan Glück

8

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

language of work or name

0 references

publication date

1 March 2013

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Expert Opinion on Investigational Drugs

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

299-307

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.766715

21 January 2018

The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.766715

21 January 2018

Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.766715

21 January 2018

Phase II trial in Japan of sequential administration of weekly paclitaxel followed by FEC as neoadjuvant chemotherapy for locally advanced breast cancer [KBCSG0206 trial: Kinki Breast Cancer Study Group (KBCSG)].

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.766715

21 January 2018

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.766715

21 January 2018

Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.766715

21 January 2018

Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.766715

21 January 2018

Phase ii trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.766715

21 January 2018

Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.766715

21 January 2018

Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.766715

21 January 2018

Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.766715

21 January 2018

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.766715

21 January 2018

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.766715

21 January 2018

Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.766715

21 January 2018

Phase II clinical trials in oncology: strengths and limitations of two-stage designs

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.766715

21 January 2018

Significance of histopathological evaluation in primary therapy for breast cancer--recent trends in primary modality with pathological complete response (pCR) as endpoint

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.766715

21 January 2018

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.766715

21 January 2018

Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.766715

21 January 2018

COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.766715

21 January 2018

Serial changes in the expression of breast cancer-related proteins in response to neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.766715

21 January 2018

Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.766715

21 January 2018

Identifiers

10.1517/13543784.2013.766715

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

release_txlc66sxcjagvouturjj3wjvpi

1 reference

https://api.fatcat.wiki/v0/release/txlc66sxcjagvouturjj3wjvpi

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44885072&oldid=2055154543"